Cargando…
p53-Based cyclotherapy: exploiting the ‘guardian of the genome' to protect normal cells from cytotoxic therapy
Side effects of chemotherapy are a major impediment in the treatment of cancer. Cyclotherapy is an emerging therapeutic strategy for protecting normal cells from the side effects of chemotherapy. Low, non-genotoxic doses of known p53 activators can be used to induce p53-dependent cell cycle arrest i...
Autores principales: | Rao, B, Lain, S, Thompson, A M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859955/ https://www.ncbi.nlm.nih.gov/pubmed/24231949 http://dx.doi.org/10.1038/bjc.2013.702 |
Ejemplares similares
-
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy
por: Rao, Bhavya, et al.
Publicado: (2010) -
Cyclotherapy: opening a therapeutic window in cancer treatment
por: van Leeuwen, Ingeborg M.M.
Publicado: (2012) -
The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016) -
The Maintenance of Epigenetic States by p53: The Guardian of the Epigenome
por: Levine, Arnold J., et al.
Publicado: (2012) -
Mutant p53 as a guardian of the cancer cell
por: Mantovani, Fiamma, et al.
Publicado: (2018)